A Study of the clinical Utility, patient preference and cost benefit of Spect and PET-CT brain imaging in the Evaluation and Diagnosis of Alzheimer's Disease

A multicentre cohort study of the clinical utility, patient preference and cost benefit of single photon emission computed tomography (SPECT) and positron emission tomography computed tomography (PET-CT) brain imaging in the evaluation and diagnosis of Alzheimer's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN49486383

Enrollment

100

Registered

2010-05-12

Start date

2010-04-01

Completion date

Unknown

Last updated

2017-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Dementias and Neurodegenerative Diseases Research Network

Interventions

Clinical assessment: Motor features of parkinsonism will be assessed using the motor subsection of the Unified Parkinson's Disease Rating Scale (UPDRS III). Cognitive assessment: This will involve Co

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of probable Alzheimer's disease or probable dementia with Lewy bodies or healthy age matched controls 2. Aged over 60 years, either sex 3. Dementia patients to have mild to moderate dementia severity (mini mental state examination [MMSE] greater than 12) 4. Sufficient English to complete cognitive and psychiatric ratings

Exclusion criteria

Exclusion criteria: 1. Physical disability that would render the patient unable to undergo PET and SPECT scanning 2. Contraindications to PET or SPECT scanning 3. Unwillingness to undergo scanning

Design outcomes

Primary

Measure	Time frame
Visual Reporting of scans (PET and SPECT), measured at baseline	—

Secondary

Measure	Time frame
1. Patient preference and cost, measured at end of recruitment phase 2. PET and SPECT maps compared for patients, measured at end of recruitment phase 3. Semi-automated region of interest analysis, measured at end of recruitment phase 4. Visual ratings of medial temporal lobe atrophy using the Scheltens scale, measured at end of recruitment phase 5. Visual ratings of scans on a semi-quantitative 4-point scale, measured at end of recruitment phase 6. Voxel based analysis using SPM5, measured at end of recruitment phase	—

Measure

Time frame

1. Patient preference and cost, measured at end of recruitment phase 2. PET and SPECT maps compared for patients, measured at end of recruitment phase 3. Semi-automated region of interest analysis, measured at end of recruitment phase 4. Visual ratings of medial temporal lobe atrophy using the Scheltens scale, measured at end of recruitment phase 5. Visual ratings of scans on a semi-quantitative 4-point scale, measured at end of recruitment phase 6. Voxel based analysis using SPM5, measured at end of recruitment phase

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026